1. Home
  2. INDP vs AEHL Comparison

INDP vs AEHL Comparison

Compare INDP & AEHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INDP
  • AEHL
  • Stock Information
  • Founded
  • INDP 2000
  • AEHL 1993
  • Country
  • INDP United States
  • AEHL China
  • Employees
  • INDP N/A
  • AEHL N/A
  • Industry
  • INDP Biotechnology: Pharmaceutical Preparations
  • AEHL Building Materials
  • Sector
  • INDP Health Care
  • AEHL Industrials
  • Exchange
  • INDP Nasdaq
  • AEHL Nasdaq
  • Market Cap
  • INDP 7.4M
  • AEHL 7.8M
  • IPO Year
  • INDP N/A
  • AEHL 2007
  • Fundamental
  • Price
  • INDP $0.35
  • AEHL $2.31
  • Analyst Decision
  • INDP Strong Buy
  • AEHL
  • Analyst Count
  • INDP 2
  • AEHL 0
  • Target Price
  • INDP $8.50
  • AEHL N/A
  • AVG Volume (30 Days)
  • INDP 757.0K
  • AEHL 199.7K
  • Earning Date
  • INDP 05-14-2025
  • AEHL 05-01-2025
  • Dividend Yield
  • INDP N/A
  • AEHL N/A
  • EPS Growth
  • INDP N/A
  • AEHL N/A
  • EPS
  • INDP N/A
  • AEHL N/A
  • Revenue
  • INDP N/A
  • AEHL $98,773,000.00
  • Revenue This Year
  • INDP N/A
  • AEHL N/A
  • Revenue Next Year
  • INDP N/A
  • AEHL N/A
  • P/E Ratio
  • INDP N/A
  • AEHL N/A
  • Revenue Growth
  • INDP N/A
  • AEHL 36.99
  • 52 Week Low
  • INDP $0.31
  • AEHL $1.79
  • 52 Week High
  • INDP $2.89
  • AEHL $256.40
  • Technical
  • Relative Strength Index (RSI)
  • INDP 39.89
  • AEHL 45.94
  • Support Level
  • INDP $0.31
  • AEHL $1.79
  • Resistance Level
  • INDP $0.37
  • AEHL $2.75
  • Average True Range (ATR)
  • INDP 0.04
  • AEHL 0.27
  • MACD
  • INDP 0.00
  • AEHL 0.00
  • Stochastic Oscillator
  • INDP 26.55
  • AEHL 49.06

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

About AEHL Antelope Enterprise Holdings Limited

Antelope Enterprise Holdings Ltd operates in two reportable operating segments: 1) business management consulting, information system technology consulting services including the sales of software use rights for digital data deposit platforms and asset management systems, and online social media platform development and consulting, and 2) natural gas power generation, which was in the initial development stage. The business of the Company is engaged in the PRC and U.S.

Share on Social Networks: